ADVERTISEMENT

Select Columnist:
Daniel A. Vorobiof, MD

Daniel A. Vorobiof, MD

Dr. Vorobiof is Oncology Director of the Sandton Oncology Centre, Johannesburg, South Africa, and a member of The ASCO Post’s International Editorial Board.
Latest Articles

  • Cost of Care: A Multidisciplinary Responsibility - Tuesday, February 14, 2012
  • Cancer in South Africa and the Role of the National Cancer Registry - Wednesday, April 27, 2011

Read Bio

Read Bio

ADVERTISEMENT

ADVERTISEMENT



Maintenance #Rituximab vs Retreatment Rituximab in Patients with Low–Tumor-Burden Follicular #Lymphoma http://t.co/n3GZnXAh #hematology
about 12 hours ago via web

AVEREL Trial Shows Benefit of #Bevacizumab in #HER2-positive Locally Recurrent or Metastatic #BreastCancer http://t.co/5GjE2V1T
about 14 hours ago via web

#FDA announces major actions taken to bolster the supply of #Doxil and preservative-free formulations of #methotrexate http://t.co/bPU8O0h7
about 1 days ago via web

JAK2 and MPL #Mutation #Screening: What Are the Indications and How to Interpret the Results http://t.co/npbhBSE4 #cancer #hematology
about 1 days ago via web

RT @TedOkonCOA: Votes today on tax package containing Medicare #SGR 10-mo patch. Medicare cuts paying for Medicare patch. Not good.
about 5 days ago via web

© 2010 HSP News Service, L.L.C.
Advertising  |  Disclosures  |  Contact TAP  |  Privacy Policy  |  Disclaimer